Lung cancer: Are we up to the challenge?

Current Genomics

Volumn 11, Issue 7, 2010, Pages 513-518

  Esposito, Luca ^a   Conti, Daniele ^b,c   Ailavajhala, Ramyasri ^d   Khalil, Nansie ^d   Giordano, Antonio ^b,d  

^a CROM Center of Oncology Research Mercogliano   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c Human Health Foundation Onlus   (Italy)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

Diagnostic tools for lung cancer; Epigenetics of lung cancer; Lung cancer; Oncogenes; Oncosuppressors

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CELL PROLIFERATION; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; EPIGENETICS; HEREDITY; HUMAN; LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; THORAX RADIOGRAPHY; TRANSBRONCHIAL ASPIRATION;

EID: 78649998792     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920210793175903     Document Type: Article

References (66)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer statistics, 2007. CA Cancer J. Clin., 2007, 57(1), 43-66.
2. Travis, W. D.; Travis, L. B.; Devesa, S. S. Lung cancer. Cancer, 1995, 75(1 Suppl), 191-202.
3. Schreiber, G.; McCrory, D. C. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest, 2003, 123(1 Suppl), 115S-128S.
4. Henschke, C. I.; Yankelevitz, D. F., CT screening for lung cancer: update 2007. Oncologist, 2008, 13(1), 65-78.
5. Spira, A.; Beane, J.; Shah, V.; Liu, G.; Schembri, F.; Yang, X.; Palma, J.; Brody, J. S. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc. Natl. Acad. Sci. USA, 2004, 101(27), 10143-10148.
6. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med., 2006, 355(24), 2542-2550.
7. Sone, S.; Li, F.; Yang, Z. G.; Honda, T.; Maruyama, Y.; Takashima, S.; Hasegawa, M.; Kawakami, S.; Kubo, K.; Haniuda, M.;Yamanda, T. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br. J. Cancer, 2001, 84(1), 25-32.
8. Fossella, F. V.; DeVore, R.; Kerr, R. N.; Crawford, J.; Natale, R. R.; Dunphy, F.; Kalman, L.; Miller, V.; Lee, J. S.; Moore, M.; Gandara, D.; Karp, D.; Vokes, E.; Kris, M.; Kim, Y.; Gamza, F.; Hammershaimb, L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol., 2000, 18(12), 2354-2362.
9. Wang, L.; Xiong, Y.; Sun, Y.; Fang, Z.; Li, L.; Ji, H.; Shi, T. HLungDB: an integrated database of human lung cancer research. Nucleic Acids Res., 2010, 38(Database issue), D665-9.
10. Fong, K. M.; Sekido, Y.; Gazdar, A. F.; Minna, J. D. Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax, 2003, 58(10), 892-900.
11. Herbst, R. S.; Heymach, J. V.; Lippman, S. M. Lung cancer. N. Engl. J. Med., 2008, 359(13), 1367-1380.
12. Aviel-Ronen, S.; Blackhall, F. H.; Shepherd, F. A.; Tsao, M. S. Kras mutations in non-small-cell lung carcinoma: a review. Clin. Lung Cancer, 2006, 8(1), 30-38.
13. Reissmann, P. T.; Koga, H.; Figlin, R. A.; Holmes, E. C.; Slamon, D. J. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J. Cancer Res. Clin. Oncol., 1999, 125(2), 61-70.
14. Salgia, R.; Skarin, A. T. Molecular abnormalities in lung cancer. J. Clin. Oncol., 1998, 16(3), 1207-1217.
15. Shigematsu, H.; Takahashi, T.; Nomura, M.; Majmudar, K.; Suzuki, M.; Lee, H.; Wistuba, II.; Fong, K.M.; Toyooka, S.; Shimizu, N.; Fujisawa, T.; Minna, J.D.; Gazdar, A.F. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res., 2005, 65(5), 1642-1646.
16. Buttitta, F.; Barassi, F.; Fresu, G.; Felicioni, L.; Chella, A.; Paolizzi, D.; Lattanzio, G.; Salvatore, S.; Camplese, P.P.; Rosini, S.; Iarussi, T.; Mucilli, F.; Sacco, R.; Mezzetti, A.; Marchetti, A. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int. J. Cancer, 2006, 119, 2586-2591.
17. Naoki, K.; Chen, T. H.; Richards, W. G.; Sugarbaker, D. J.; Meyerson, M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res., 2002, 62(23), 7001-7003.
18. Brose, M. S.; Volpe, P.; Feldman, M.; Kumar, M.; Rishi, I.; Gerrero, R.; Einhorn, E.; Herlyn, M.; Minna, J.; Nicholson, A.; Roth, J. A.; Albelda, S. M.; Davies, H.; Cox, C.; Brignell, G.; Stephens, P.; Futreal, P. A.; Wooster, R.; Stratton, M. R.; Weber, B. L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res., 2002, 62(23), 6997-7000.
19. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350, 2129-2139.
20. Paez, J.G.; Jänne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson M. EGFRmutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304, 1497-1500.
21. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L.; Mardis, E.; Kupfer, D.; Wilson, R.; Kris, M.; Varmus, H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci.USA, 2004, 101, 13306-13311.
22. Sequist, L.V.; Engelman, J.A.; Lynch, T.J. Toward noninvasive genomic screening of lung cancer patients. J. Clin. Oncol., 2009, 27(16), 2589-2591.
23. Sartori, G.; Cavazza, A.; Bertolini, F.; Longo, L.; Marchioni, A.; Costantini, M.; Barbieri, F.; Migaldi, M.; Rossi, G. A subset of lung adenocarcinomas and atypical adenomatous hyperplasiaassociated foci are genotypically related: an EGFR, HER2, and Kras mutational analysis. Am. J. Clin. Pathol., 2008, 129(2), 202-210.
24. Irby, R. B.; Yeatman, T. J. Role of Src expression and activation in human cancer. Oncogene, 2000, 19(49), 5636-5642.
25. Irby, R.B.; Mao, W.; Coppola, D.; Kang, J.; Loubeau, J. M.; Trudeau, W.; Karl, R.; Fujita, D. J.; Jove, R.; Yeatman, T. J. Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet., 1999, 21(2), 187-190.
26. Masaki, T.; Igarashi, K.; Tokuda, M.; Yukimasa, S.; Han, F.; Jin, Y. J.; Li, J. Q.; Yoneyama, H.; Uchida, N.; Fujita, J.; Yoshiji, H.; Watanabe, S.; Kurokohchi, K.; Kuriyama, S., pp60c-src activation in lung adenocarcinoma. Eur. J. Cancer, 2003, 39(10), 1447-1455.
27. Mazurenko, N. N.; Kogan, E. A.; Zborovskaya, I. B.; Kisseljov, F. L., Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur. J. Cancer, 1992, 28(2-3), 372-377.
28. Laird, A. D.; Li, G.; Moss, K. G.; Blake, R. A.; Broome, M. A.; Cherrington, J. M.; Mendel, D. B. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and - independent growth of human tumor cells. Mol. Cancer Ther., 2003, 2(5), 461-469.
29. Song, L.; Turkson, J.; Karras, J. G.; Jove, R.; Haura, E. B. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene, 2003, 22(27), 4150-4165.
30. Sasaki, T.; Rodig, S.J.; Chirieac, L.R.; Jänne, P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur. J. Cancer, 2010, 46(10), 1773-80.
31. Wong, D.W.; Leung, E.L.; So, K.K.; Tam, I.Y.; Sihoe, A.D.; Cheng, L.C.; Ho, K.K.; Au, J.S.; Chung, L.P.; Pik Wong, M. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 2009, 115(8), 1723-1733.
32. Devereux, T. R.; Taylor, J. A.; Barrett, J. C. Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Giles F. Filley Lecture. Chest, 1996, 109(3 Suppl), 14S-19S.
33. Ji, H.; Ramsey, M. R.; Hayes, D. N.; Fan, C.; McNamara, K.; Kozlowski, P.; Torrice, C.; Wu, M. C.; Shimamura, T.; Perera, S. A.; Liang, M. C.; Cai, D.; Naumov, G. N.; Bao, L.; Contreras, C. M.; Li, D.; Chen, L.; Krishnamurthy, J.; Koivunen, J.; Chirieac, L. R.; Padera, R. F.; Bronson, R. T.; Lindeman, N. I.; Christiani, D. C.; Lin, X.; Shapiro, G. I.; Janne, P. A.; Johnson, B. E.; Meyerson, M.; Kwiatkowski, D. J.; Castrillon, D. H.; Bardeesy, N.; Sharpless, N. E.; Wong, K. K. LKB1 modulates lung cancer differentiation and metastasis. Nature, 2007, 448(7155), 807-810.
34. Ding, L.; Getz, G.; Wheeler, D. A.; Mardis, E. R.; McLellan, M. D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D. M.; Morgan, M. B.; Fulton, L.; Fulton, R. S.; Zhang, Q.; Wendl, M. C.; Lawrence, M. S.; Larson, D. E.; Chen, K.; Dooling, D. J.; Sabo, A.; Hawes, A. C.; Shen, H.; Jhangiani, S. N.; Lewis, L. R.; Hall, O.; Zhu, Y.; Mathew, T.; Ren, Y.; Yao, J.; Scherer, S. E.; Clerc, K.; Metcalf, G. A.; Ng, B.; Milosavljevic, A.; Gonzalez-Garay, M. L.; Osborne, J. R.; Meyer, R.; Shi, X.; Tang, Y.; Koboldt, D. C.; Lin, L.; Abbott, R.; Miner, T. L.; Pohl, C.; Fewell, G.; Haipek, C.; Schmidt, H.; Dunford-Shore, B. H.; Kraja, A.; Crosby, S. D.; Sawyer, C. S.; Vickery, T.; Sander, S.; Robinson, J.; Winckler, W.; Baldwin, J.; Chirieac, L. R.; Dutt, A.; Fennell, T.; Hanna, M.; Johnson, B. E.; Onofrio, R. C.; Thomas, R. K.; Tonon, G.; Weir, B. A.; Zhao, X.; Ziaugra, L.; Zody, M. C.; Giordano, T.; Orringer, M. B.; Roth, J. A.; Spitz, M. R.; Wistuba, II; Ozenberger, B.; Good, P. J.; Chang, A. C.; Beer, D. G.; Watson, M. A.; Ladanyi, M.; Broderick, S.; Yoshizawa, A.; Travis, W. D.; Pao, W.; Province, M. A.; Weinstock, G. M.; Varmus, H. E.; Gabriel, S. B.; Lander, E. S.; Gibbs, R. A.; Meyerson, M.; Wilson, R. K. Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008, 455(7216), 1069-1075.
35. Slack-Davis, J.; Dasilva, J.O.; Parsons, S.J. LKB1 and Src: Antagonistic Regulators of Tumor Growth and Metastasis. Cancer Cell, 2010, 17(6), 547-559.
36. Classon, M.; Harlow, E. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer, 2002, 2(12), 910-917.
37. Sherr, C. J.; McCormick, F. The RB and p53 pathways in cancer. Cancer Cell, 2002, 2(2), 103-112.
38. Grasemann, C.; Gratias, S.; Stephan, H.; Schuler, A.; Schramm, A.; Klein-Hitpass, L.; Rieder, H.; Schneider, S.; Kappes, F.; Eggert, A.; Lohmann, D. R. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene, 2005, 24(42), 6441-6449.
39. Olsson, A. Y.; Feber, A.; Edwards, S.; Te Poele, R.; Giddings, I.; Merson, S.; Cooper, C. S. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene, 2007, 26(7), 1028-1037.
40. Wistuba, II; Gazdar, A. F.; Minna, J. D. Molecular genetics of small cell lung carcinoma. Semin. Oncol., 2001, 28(2 Suppl 4), 3-13.
41. Ho, V. M.; Schaffer, B. E.; Karnezis, A. N.; Park, K. S.; Sage, J. The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. Oncogene, 2009, 28(10), 1393-1399.
42. Engels, E. A.; Wu, X.; Gu, J.; Dong, Q.; Liu, J.; Spitz, M. R. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res., 2007, 67(13), 6520-6527.
43. Wenzlaff, A. S.; Cote, M. L.; Bock, C. H.; Land, S. J.; Santer, S. K.; Schwartz, D. R.; Schwartz, A. G. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population- based study. Carcinogenesis, 2005, 26(12), 2207-2212.
44. Son, J. W.; Kang, H. K.; Chae, M. H.; Choi, J. E.; Park, J. M.; Lee, W. K.; Kim, C. H.; Kim, D. S.; Kam, S.; Kang, Y. M.; Park, J. Y. Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer, Genet. Cytogenet., 2006, 169(2), 121-127.
45. Yin, J.; Vogel, U.; Ma, Y.; Qi, R.; Sun, Z.; Wang, H. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer, 2007, 56(2), 153-160.
46. Zochbauer-Muller, S.; Fong, K. M.; Virmani, A. K.; Geradts, J.; Gazdar, A. F.; Minna, J. D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res., 2001, 61(1), 249-255.
47. Seike, M.; Gemma, A.; Hosoya, Y.; Hemmi, S.; Taniguchi, Y.; Fukuda, Y.; Yamanaka, N.; Kudoh, S. Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53.Clin. Cancer Res., 2000, 6(11), 4307-4313.
48. Kersting, M.; Friedl, C.; Kraus, A.; Behn, M.; Pankow, W.; Schuermann, M. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol., 2000, 18(18), 3221-3229.
49. Sato, M.; Mori, Y.; Sakurada, A.; Fujimura, S.; Horii, A. The Hcadherin(CDH13) gene is inactivated in human lung cancer. Hum. Genet., 1998, 103(1), 96-101.
50. Tang, X.; Khuri, F. R.; Lee, J. J.; Kemp, B. L.; Liu, D.; Hong, W. K.; Mao, L. Hypermethylation of the death-associated protein(DAP) kinase promoter and aggressiveness in stage I nonsmall- cell lung cancer. J. Natl. Cancer Inst., 2000, 92(18), 1511-1516.
51. Osada, H.; Tatematsu, Y.; Yatabe, Y.; Nakagawa, T.; Konishi, H.; Harano, T.; Tezel, E.; Takada, M.; Takahashi, T. Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene, 2002, 21(15), 2418-2424.
52. Dammann, R.; Li, C.; Yoon, J. H.; Chin, P. L.; Bates, S.; Pfeifer, G. P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet., 2000, 25(3), 315-319.
53. Lagos-Quintana, M.; Rauhut, R.; Lendeckel, W.; Tuschl, T., Identification of novel genes coding for small expressed RNAs. Science, 2001, 294(5543), 853-858.
54. Lau, N. C.; Lim, L. P.; Weinstein, E. G.; Bartel, D. P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science, 2001, 94(5543), 858-862.
55. Lee, R. C.; Ambros, V. An extensive class of small RNAs in Caenorhabditis elegans. Science, 2001, 294(5543), 862-864.
56. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R. M.; Okamoto, A.; Yokota, J.; Tanaka, T.; Calin, G. A.; Liu, C. G.; Croce, C. M.; Harris, C. C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 2006, 9(3), 189-198.
57. Gee, G. V.; Koestler, D. C.; Christensen, B. C.; Sugarbaker, D. J.; Ugolini, D.; Ivaldi, G. P.; Resnick, M. B.; Houseman, E. A.; Kelsey, K. T.; Marsit, C. J. Downregulated MicroRNAs in the differential diagnosis of malignant pleural mesothelioma. Int. J. Cancer, 2010, [Epub ahead of print].
58. Fabbri, M.; Garzon, R.; Cimmino, A.; Liu, Z.; Zanesi, N.; Callegari, E.; Liu, S.; Alder, H.; Costinean, S.; Fernandez-Cymering, C.; Volinia, S.; Guler, G.; Morrison, C. D.; Chan, K. K.; Marcucci, G.; Calin, G. A.; Huebner, K.; Croce, C. M. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA, 2007, 104(40), 15805-15810.
59. Takahashi, Y.; Forrest, A. R.; Maeno, E.; Hashimoto, T.; Daub, C. O.; Yasuda, J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One, 2009, 4(8), e6677.
60. Bandi, N.; Zbinden, S.; Gugger, M.; Arnold, M.; Kocher, V.; Hasan, L.; Kappeler, A.; Brunner, T.; Vassella, E. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res., 2009, 69(13), 5553-5559.
61. Lantuéjoul, S.; Salon, C.; Soria, JC.; Brambilla, E. Telomerase expression in lung preneoplasia and neoplasia. Int. J. Cancer, 2007, 120, 1835-1841.
62. Leidinger, P.; Keller, A.; Heisel, S.; Ludwig, N.; Rheinheimer, S.; Klein, V.; Andres, C.; Staratschek-Jox, A.; Wolf, J.; Stoelben, E.; Stephan, B.; Stehle, I.; Hamacher, J.; Huwer, H.; Lenhof, H. P.; Meese, E. Identification of lung cancer with high sensitivity and specificity by blood testing. Respir. Res., 2010, 11, 18.
63. Goksel, T.; Akkoclu, A. Pattern of lung cancer in Turkey, 1994-1998. Respiration, 2002, 69(3), 207-210.
64. Bai, H.; Mao, L.; Wang, H.S.; Zhao, J.; Yang, L.; An, T.T.; Wang, X.; Duan, C.J.; Wu, N.M.; Guo, Z.Q.; Liu, Y.X.; Liu, H.N.; Wang, Y.Y.; Wang, J. Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer. J. Clin. Oncol., 2009, 27, 2653-2659.
65. Ceppi, P.; Papotti, M.; Scagliotti, G. New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS. Adv. Med. Sci., 2010, 55(1), 22-5.
66. Su, C.; Zhou, S.; Zhang, L.; Ren, S.; Xu, J.; Zhang, J.; Lv, M.; Zhang, J.; Zhou, C. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med. Oncol., 2010, [Epub ahead of print].